Otsuka amplifies research-based mental health program, adds first digital accessnews2023-12-01T17:09:17+00:00December 1st, 2023|Endpoints News|
Exclusive: San Diego biotech raises $11.7M to use cells as targeted delivery vessels for genetic medicinesnews2023-12-01T16:30:45+00:00December 1st, 2023|Endpoints News|
Tharimmune’s public offering; Culmination Bio raises $10M; Pepper Bio’s seed round led by NFXnews2023-12-01T15:46:33+00:00December 1st, 2023|Endpoints News|
ARCH-allied AN Venture Partners raises $200M to build biotechs out of research from Japannews2023-12-01T13:33:36+00:00December 1st, 2023|Endpoints News|
Tang’s Concentra shifts gears with unsolicited bid for LianBio after previously targeting struggling biotechsnews2023-12-01T12:08:51+00:00December 1st, 2023|Endpoints News|
Amylyx hires new CMO from Ultragenyx; Eliot Forster is back as a CEO after F-star salenews2023-12-01T11:57:26+00:00December 1st, 2023|Endpoints News|
Pfizer abandons twice-daily GLP-1 approach due to high discontinuation rates, goes back to PhI with once-a-day dosenews2023-12-01T11:45:03+00:00December 1st, 2023|Endpoints News|
Altimmune reports 15.6% weight loss in PhII obesity trial after longer follow-upnews2023-12-01T11:39:39+00:00December 1st, 2023|Endpoints News|
AstraZeneca halts two PhIII hyperkalemia studies intended to spotlight Lokelma’s clinical valuenews2023-12-01T11:29:43+00:00December 1st, 2023|Endpoints News|
Perpetual Medicines raises $8M seed round to apply machine learning in peptide drug discoverynews2023-12-01T01:00:20+00:00December 1st, 2023|Endpoints News|
